

Characterising spillover effects and carer burden in X-linked hypophosphataemia

Claire Lawrence¹, Elina Matter¹, Linda McNamara², Victoria Hayes³, Andrew Lloyd¹
¹Acaster Lloyd Consulting, Research, London, United Kingdom; ²Employee of Kyowa Kirin Ltd., Marlow, United Kingdom at the time the research was conducted; ³Kyowa Kirin Ltd., Marlow, United Kingdom



KEY FINDINGS

Qualitative findings indicate that carers and family members provide considerable support for adults with XLH resulting in a broad range of impacts to carers and family members’ lives and highlight areas of carer-burden not well captured by the EQ-5D.

INTRODUCTION AND OBJECTIVE

- Health-related quality of life (HRQoL) impacts of disease extend beyond the patient.
- ‘Spillover effects’ are the HRQoL impacts experienced by any individual in contact with a patient - carers, family members, partners and friends.
- X-linked hypophosphataemia (XLH) is a chronic rare metabolic bone disease, with a high disease burden (1,2).
- XLH is genetic and in many cases hereditary, with carers of XLH patients often being patients themselves.
- To date, no research has explored the possible spillover effects of XLH.

OBJECTIVE: To describe the spillover effects of XLH and measure their impacts on carers and family members of adults with XLH.

METHODS

- Informal carers and family members of adults with XLH completed the study and were recruited through XLH UK, the UK patient organisation supporting people with XLH.
- All participants provided informed consent. The study protocol was reviewed by an Independent Review Board.
- Quantitative data collected included: (1) participants’ and care recipients’ demographic and clinical information; (2) the EQ-5D-5L; (3) the Work Productivity and Activity Impairment (WPAI) questionnaire (3).
- Qualitative data were collected via one-to-one semi-structured interviews conducted virtually (Via Zoom or telephone).

QUANTITATIVE FINDINGS

- Twenty informal carers or family members of adults with XLH took part in the study. Four participants had XLH themselves.
- The mean age of participants was 48.5 years (range 26-83) and the majority were male (N=13/20; 65%).
- The WPAI revealed an overall work impairment of 28% and activity impairment of 42%.
- The EQ-5D-5L demonstrated lower HRQoL for informal carers and family members of adults with XLH compared to the UK general population data.
- Informal carers with XLH (n=4) had much lower HRQoL compared to both informal carers without XLH (n=16) and the UK general population.
- Informal carers without XLH had HRQoL only slightly less than that of the UK general population. **(Figure 1)**





Figure 1. EQ-5D-5L Utility scores of participants versus UK General Population

QUALITATIVE FINDINGS

- Informal carers and family members provide adults with XLH support in several areas.
- Providing support for adults with XLH resulted in spillover effects on participants’ HRQoL, with impacts greatest among informal carers with XLH **(Figure 2)**.
- Although on the EQ-5D-5L most carers without XLH reported ‘no problems’ on the usual activities, and, ‘no problems’ or ‘slight problems’ on the anxiety and depression domains, almost all participants qualitatively described substantial impacts to their daily activities and their emotional wellbeing.

Figure 2. Health-related quality of life impacts experienced by carers and family members of XLH patients



CONCLUSIONS

- This study highlights the substantial spillover effects of XLH.
- The disparity between the EQ-5D utility data and the substantial burden reported in the qualitative data for carers without XLH in the domains of usual activities, and, anxiety and depression, raises important questions about the appropriateness of the EQ-5D to measure spillover effects in XLH and other disease areas.

REFERENCES

1. Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, et al. (2019). The lifelong impact of X-linked hypophosphataemia: Results from a burden of disease survey. *Journal of the Endocrine Society*. 3(7), 1321–34.
2. Carpenter TO, Imel EA, Holm IA, Jan De Beur SM, Insogna KL. (2011). A clinician’s guide to X-linked hypophosphataemia. *Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research*. 26(7), 1381-1388.
3. Reilly, M.c., Zbrozek, A. S., & Dukes, E. M. (1993). The validity and reproducibility of a work productivity and activity impairment instrument. *PharmcoEconomics*. 4(5), 353-365.

ACKNOWLEDGMENTS AND DISCLOSURES

We would like to acknowledge the participants who contributed to this project as well as XLH UK who supported participant recruitment. This work was supported and fully funded by Kyowa Kirin Ltd.